TEVA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	9.74M
Average Volume	10.49M
Market Cap	14.42B
EPS	$0 ( 2024-02-14 )
Next earnings date	( $0.510 ) 2024-05-08
Last Dividend	$0.0850 ( 2017-11-27 )
Next Dividend	$0 ( N/A )
P/E	-25.72
ATR14	$0.0120 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-05	Kalif Eliyahu Sharon	Buy	21 387	Ordinary Shares
2024-03-05	Kalif Eliyahu Sharon	Buy	52 320	Ordinary Shares
2024-03-06	Kalif Eliyahu Sharon	Sell	77 550	Ordinary Shares
2024-03-05	Kalif Eliyahu Sharon	Sell	21 387	Restricted Share Units
2024-03-05	Kalif Eliyahu Sharon	Sell	52 320	Restricted Share Units

INSIDER POWER
16.81
Last 98 transactions
Buy: 2 305 980 \| Sell: 1 612 593

Volume Correlation

Long: -0.02 (neutral)

Short: -0.31 (neutral)

Signal:(52.647) Neutral

Teva Pharmaceutical Correlation

10 Most Positive Correlations
UHS	0.848
NTZ	0.825
TGS	0.809
THD	0.809
VZ	0.805

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Teva Pharmaceutical Correlation - Currency/Commodity

-0.46
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.45
( neutral )

0.38
( neutral )

0.58
( weak )

Teva Pharmaceutical Financials

Annual	2023
Revenue:	$15.85B
Gross Profit:	$7.65B (48.25 %)
EPS:	$-0.500

Q4	2023
Revenue:	$4.46B
Gross Profit:	$2.42B (54.21 %)
EPS:	$0.410

Q3	2023
Revenue:	$3.85B
Gross Profit:	$1.85B (48.08 %)
EPS:	$0.0714

Q2	2023
Revenue:	$3.88B
Gross Profit:	$1.80B (46.31 %)
EPS:	$-0.770

Financial Reports:

No articles found.

Teva Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Teva Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 4.54 - low (50.68%) | Divividend Growth Potential Score: 0.416 - No dividend growth expected in the near future

Information

First Dividend	$0.00188	1987-02-23
Last Dividend	$0.0850	2017-11-27
Next Dividend	$0	N/A
Payout Date	2017-12-12
Next Payout Date	N/A
# dividends	125	--
Total Paid Out	$11.76	--
Avg. Dividend % Per Year	0.00%	--
Score	3.24	--
Div. Sustainability Score	4.54
Div.Growth Potential Score	0.416
Div. Directional Score	2.48	--

Next Divdend (Est)
(2024-06-10)

$0 Estimate 0.00 %

Dividend Stability

0.17 Bad

Dividend Score

3.24

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
1987	$0.00802	1.94%
1988	$0.00964	2.40%
1989	$0.00807	1.81%
1990	$0.00919	1.23%
1991	$0.00938	1.28%
1992	$0.0105	0.75%
1993	$0.0161	0.56%
1994	$0.0175	0.46%
1995	$0.0271	0.90%
1996	$0.0250	0.43%
1997	$0.0310	0.50%
1998	$0.0411	0.68%
1999	$0.0276	0.52%
2000	$0.0413	0.47%
2001	$0.0648	0.39%
2002	$0.0906	0.59%
2003	$0.163	0.83%
2004	$0.201	0.69%
2005	$0.269	0.92%
2006	$0.306	0.69%
2007	$0.385	1.23%
2008	$0.503	1.07%
2009	$0.605	1.42%
2010	$0.748	1.29%
2011	$0.901	1.71%
2012	$1.034	2.40%
2013	$1.278	3.44%
2014	$1.366	3.39%
2015	$1.360	2.42%
2016	$1.360	2.08%
2017	$0.850	2.27%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NYSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
LOMA	Dividend Knight	2023-06-30	Quarterly	2	5.23%	8.53
SCM	Dividend King	2023-12-15	Monthly	13	7.08%	8.50
SJT	Dividend Royal	2023-11-29	Monthly	39	12.52%	8.50
ZTR	Dividend King	2024-02-09	Monthly	37	8.35%	8.50
SRV	Dividend Royal	2023-12-04	Monthly	18	7.53%	8.50
PHK	Dividend Royal	2023-11-10	Monthly	22	6.88%	8.50
JQC	Dividend Royal	2023-11-14	Monthly	22	6.56%	8.50
GOF	Dividend Royal	2023-11-14	Monthly	18	8.03%	8.50
PCF	Dividend King	2023-12-18	Monthly	38	7.05%	8.50
PVL	Dividend Royal	2023-11-15	Monthly	14	9.37%	8.50

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0353	1.500	-0.706	-1.058	[0 - 0.5]
returnOnAssetsTTM	-0.0129	1.200	-0.429	-0.514	[0 - 0.3]
returnOnEquityTTM	-0.0762	1.500	-1.958	-2.94	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.019	0.800	9.90	7.92	[1 - 3]
quickRatioTTM	0.542	0.800	-1.520	-1.216	[0.8 - 2.5]
cashRatioTTM	0.263	1.500	9.65	10.00	[0.2 - 2]
debtRatioTTM	0.464	-1.500	2.27	-3.41	[0 - 0.6]
interestCoverageTTM	0.914	1.000	-0.773	-0.773	[3 - 30]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.751	2.00	9.62	10.00	[0 - 20]
debtEquityRatioTTM	2.68	-1.500	10.00	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.482	1.000	5.29	5.29	[0.2 - 0.8]
operatingProfitMarginTTM	0.0593	1.000	-0.814	-0.814	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.0679	1.000	-0.734	-0.734	[0.2 - 2]
assetTurnoverTTM	0.364	0.800	-0.904	-0.723	[0.5 - 2]
Total Score				4.54

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-27.77	1.000	-2.91	0	[1 - 100]
returnOnEquityTTM	-0.0762	2.50	-1.259	-2.94	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.751	2.00	9.75	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.220	2.00	9.59	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.445	1.500	-6.30	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0863	1.000	-0.342	0	[0.1 - 0.5]
Total Score				0.416

Teva Pharmaceutical

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.